You are here

  • Home
  • Archive
  • Volume 27, Issue 6
  • Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain

Article metrics

Article menu
Download PDFPDF
Original research
Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain

 

Online download statistics by month:

Online download statistics by month: May 2019 to March 2024

AbstractFullPdf
May 20198911114
Jun 201969612
Jul 201971553
Aug 20196022010
Sep 201983874
Oct 2019121311
Nov 201966762
Dec 201918833
Jan 202017822
Feb 202016231
Mar 202011941
Apr 202011713
May 202012031
Jun 202013655
Jul 202013117
Aug 20209701
Sep 202012374
Oct 202013451510
Nov 20206031110
Dec 202043164
Jan 202121852
Feb 202121343
Mar 202122231
Apr 202111426
May 20215920
Jun 2021932
Jul 2021400
Aug 2021310
Sep 2021213
Oct 202115342
Nov 202110810
Dec 202120530
Jan 202220710
Feb 202213010
Mar 202216823
Apr 202212900
May 202213610
Jun 2022941610
Jul 2022505011
Aug 2022646124
Sep 2022534921
Oct 2022636520
Nov 2022696317
Dec 2022434020
Jan 202323200
Feb 202310620
Mar 20237111
Apr 20236442
May 20235001
Jun 202310520
Jul 20236410
Aug 202312200
Sep 20238540
Oct 20237800
Nov 20239532
Dec 202311700
Jan 202412715
Feb 202411605
Mar 202427200
Total13592508249